As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray
ARS Pharmaceuticals is backing onto Nasdaq through a reverse merger with Silverback Therapeutics to bag cash to commercialize an epinephrine nasal spray and win market share from the incumbent EpiPen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results